These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22753584)

  • 1. Overestimation of the effect size in group sequential trials.
    Zhang JJ; Blumenthal GM; He K; Tang S; Cortazar P; Sridhara R
    Clin Cancer Res; 2012 Sep; 18(18):4872-6. PubMed ID: 22753584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.
    Mauer M; Collette L; Bogaerts J;
    Eur J Cancer; 2012 Jun; 48(9):1386-91. PubMed ID: 22281098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
    Bhattacharya S; Fyfe G; Gray RJ; Sargent DJ
    J Clin Oncol; 2009 Dec; 27(35):5958-64. PubMed ID: 19826121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.
    Stallard N
    Stat Med; 2010 Apr; 29(9):959-71. PubMed ID: 20191605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of early efficacy endpoints for proof-of-concept trials.
    Chen C; Sun L; Li CL
    J Biopharm Stat; 2013 Mar; 23(2):413-24. PubMed ID: 23437947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group sequential and adaptive designs: a novel, promising tool for nursing research.
    Baldi I; Gouchon SM; Di Giulio P; Buja A; Gregori D
    J Adv Nurs; 2011 Aug; 67(8):1824-33. PubMed ID: 21517937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.
    Denne JS; Stone AM; Bailey-Iacona R; Chen TT
    J Biopharm Stat; 2013; 23(5):951-70. PubMed ID: 23957509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When are "positive" clinical trials in oncology truly positive?
    Ocana A; Tannock IF
    J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seamless phase II/III designs.
    Stallard N; Todd S
    Stat Methods Med Res; 2011 Dec; 20(6):623-34. PubMed ID: 20724313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive increase in sample size when interim results are promising: a practical guide with examples.
    Mehta CR; Pocock SJ
    Stat Med; 2011 Dec; 30(28):3267-84. PubMed ID: 22105690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-designing trial combined with classical group sequential monitoring.
    Yin G; Shen Y
    J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.